When should the PREVENT tool be used and how is the 10‑year ASCVD risk score applied for primary prevention in adults aged 40–75 without known atherosclerotic cardiovascular disease?

When to Use PREVENT and the 10-Year Risk Score

Use the PREVENT equations to calculate 10-year ASCVD risk in adults aged 30-79 years without known cardiovascular disease, particularly for those aged 40-75 years when making primary prevention treatment decisions. The PREVENT tool represents the most contemporary risk assessment method, replacing the older Pooled Cohort Equations (PCE) with improved accuracy and calibration 1, 2.

Target Population for Risk Assessment

Calculate 10-year ASCVD risk routinely in adults aged 40-75 years as part of primary prevention evaluation 3. For younger adults aged 20-39 years, assess traditional ASCVD risk factors at least every 4-6 years, though formal risk calculation may be deferred 3. Risk assessment should be repeated every 4-6 years in those without established cardiovascular disease 3.

When NOT to Calculate Risk

Do not calculate 10-year ASCVD risk in patients who already qualify for statin therapy based on clinical criteria alone 3:

• Adults with established clinical ASCVD (prior MI, stroke, TIA, angina, coronary revascularization, or peripheral arterial disease) 3
• Adults with LDL-C ≥190 mg/dL (severe primary hypercholesterolemia) 3
• Adults aged 40-75 years with diabetes and LDL-C ≥70 mg/dL (though risk calculation may guide intensity of therapy) 3

PREVENT vs. Pooled Cohort Equations

PREVENT equations provide more accurate risk prediction than the PCE, particularly avoiding the systematic overestimation seen with older calculators 1, 2. Key improvements include:

• Substantially lower predicted risk: Mean 10-year ASCVD risk is approximately 4.3% with PREVENT versus 8.0% with PCE in the same population 4
• Better calibration: PREVENT demonstrates superior calibration with observed-to-expected ratios closer to 1.0, while PCE consistently overestimates risk 2, 5
• Race-free calculation: PREVENT removes race as a variable while adding kidney function (eGFR) and current statin use 4, 1
• Contemporary derivation: Based on data from 1992-2017 with validation in over 3 million participants 1

Clinical Application of Risk Thresholds

For adults aged 40-75 years without diabetes and LDL-C 70-189 mg/dL, use these risk thresholds to guide statin therapy decisions 3:

High Risk (≥20% 10-year ASCVD risk)

• Initiate high-intensity statin therapy to reduce LDL-C by ≥50% 3
• Strong recommendation with clear benefit 3

Intermediate Risk (7.5-19.9% 10-year ASCVD risk)

• Initiate moderate-intensity statin therapy to reduce LDL-C by ≥30% after clinician-patient risk discussion 3
• Consider risk-enhancing factors (family history of premature ASCVD, persistently elevated LDL-C ≥160 mg/dL, metabolic syndrome, chronic kidney disease, inflammatory disorders, elevated triglycerides ≥175 mg/dL) 3
• If decision remains uncertain, measure coronary artery calcium (CAC) score: CAC=0 may defer therapy (except in smokers, diabetics, or strong family history); CAC 1-99 favors therapy especially if age ≥55; CAC ≥100 or ≥75th percentile indicates statin therapy 3

Borderline Risk (5-7.5% 10-year ASCVD risk)

• Consider moderate-intensity statin therapy in selected individuals with risk-enhancing factors after discussion 3
• CAC scoring may help refine decision-making 3

Low Risk (<5% 10-year ASCVD risk)

• Emphasize lifestyle modification; statin therapy generally not recommended unless compelling risk-enhancing factors present 3

Impact of PREVENT Implementation

Adoption of PREVENT equations will substantially reduce the number of adults recommended for statin therapy compared to PCE-based recommendations 4, 6:

• Approximately 17.3 million fewer Americans would meet criteria for primary prevention statins using PREVENT versus PCE 4
• The proportion classified as high-risk (≥20%) drops from 12.5% with PCE to 0.4% with PREVENT 6
• Most dramatic reductions occur in Black adults and those aged 70-75 years 4

Critical Caveats

PREVENT equations may underestimate risk in certain populations 7. In people with HIV, PREVENT underpredicted actual ASCVD events with observed-to-expected ratio of 2.69, suggesting need for clinical judgment in special populations 7.

The clinician-patient risk discussion remains essential before initiating statin therapy, covering major risk factors, risk-enhancing factors, potential benefits and harms, drug interactions, costs, and patient preferences 3. This discussion should not be replaced by algorithmic decision-making alone 3.

For adults >75 years, risk assessment and treatment decisions require individualized clinical judgment as evidence is more limited, though PREVENT demonstrates good discrimination in this age group 3, 5.